ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX

Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. alleging securities fraud that affected investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that the defendants made false statements regarding the efficacy of masofaniten in combination with enzalutamide, suggesting it had no clear benefit over enzalutamide alone [2] - It is alleged that masofaniten was less effective in treating prostate cancer than previously communicated to investors [2] - The M-E Combination Study was reportedly unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the defendants' public statements [2] - Defendants are accused of overstating masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4] - The firm has over 70 employees dedicated to serving clients in complex securities litigation [4]